---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037840"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:03:39.972562+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine shareholders approve repricing of up to 8.3M stock options to $4.04/sh

## Summary
- Stockholders approved one-time repricing of eligible options held by employees, execs, and board; exercise price reduced to $4.04 (Aug 1 closing price).
- Covers up to 8,285,387 shares; options revert to original price if exercised before 1-yr (employees) or 18-mo (executives/board) retention period unless certain conditions.
- Final vote: 71.6M for, 13.5M against, 0.1M abstain.
- CEO Allan Reine and other named exec officers are eligible optionholders.
- Repricing intended as retention mechanism; original terms except exercise price remain.

## SEC filing metadata
- accession: 0001628280-25-037840
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828025037840/0001628280-25-037840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828025037840/prme-20250801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037840
- JSON: https://secwatch.observer/filing/0001628280-25-037840.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.